Ligand Buys Ryjunea Royalty Rights for $23M, Adding First Approved Pediatric Myopia Drug
LGND sits 77% above its 52-week low of $163.45.
Summary
Ligand acquired a tiered royalty interest in Santen's Ryjunea from Sydnexis for $23 million upfront. The deal gives Ligand a low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa, plus milestone payments. Ryjunea is the first and only approved pharmacological treatment for pediatric myopia in the EU and UK, addressing a large and growing market. This adds a differentiated, commercial-stage asset to Ligand's royalty portfolio, which already spans over 200 assets following the XOMA acquisition. The modest upfront cost relative to Ligand's market cap and the product's first-mover status make this a meaningful portfolio addition.
At the time of this announcement, LGND was trading at $290.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $163.45 to $326.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.